Milestones achieved

MILESTONES ACHIEVED

03 2020 COVIRIX Medical Pty Ltd incorporated (ACN 639 682 607)
CVX 20733 Identified as ideal drug for repurposing. Approved drug for non-infective use with known action vs SARS-CoV-2
08 2020 MOU with COVID Pharmaceutical Pty Ltd for license to develop and repurpose CVX 20733 and related compounds for both anti-viral and anti-inflammatory therapies
Provisional Patent filed for use of 20733 and related compounds as an anti-COVID-19 drug for delivery via inhalation, nebulization & intra-nasal routes
Start of 1st Tranche Capital Raise
09 2020 Engagement of Prof Simon Tucker as Chief Virologist & Head of Clinical Development
MOU with Deakin University, Melbourne for service engagement of Prof David Morton as Consultant Aerosol Scientist
11 2020 Antiviral Studies vs SARS C0V-2 at Southern Research (SR) Laboratories, USA.
12 2020 Market intelligence of preliminary antiviral efficacy for 20755 and 20788 in hand from SR Laboratories, USA
12 2020 Formulation work commenced for inhalational delivery
03 2021 Completed virology test data sharing agreement with Walter & Eliza Hall Institute on CVX 20733, CVX 20755
05 2021 Completion of satisfactory revalidation tests of CVX 20733 (+ 20755 & 20788) antiviral activity vs UK and South African variants of SARS-CoV-2 at ViroClinics, Netherlands
05 2021 Tranche 2 Capital Raise commenced
06 2021 NDA signed with major European API & pharmaceutical company with global production/distribution chain
06 2021 Identified GMP Facilities in India & Nepal for manufacture of CVX 20733 (Nebulised formulation)
NDA with CRO in India and established communication with Government agencies in Zimbabwe and Nepal for accelerating Re-Phase I (Pharmacokinetic), Dose escalation Phase I, and II Studies
08 2021 MOU with Medical Ventures Pvt Ltd – CRO support for clinical trials in Nepal
09 2021 Asian Pharmaceuticals Pvt Ltd – GMP Manufacturer for clinical trials in Nepal
Q1 2023 Granted Patent in Australia
Q2 2023 Submissions for Patent positions in US, EU, China and Japan

Milestones achieved

ESTABLISHED INDUSTRY RELATIONSHIPS 2020

ESTABLISHED INDUSTRY RELATIONSHIPS 2021

Address

Contacts

Links